Compare MLYS & FMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLYS | FMC |
|---|---|---|
| Founded | 2019 | 1910 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | 2023 | N/A |
| Metric | MLYS | FMC |
|---|---|---|
| Price | $31.07 | $16.01 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 14 |
| Target Price | ★ $47.33 | $20.69 |
| AVG Volume (30 Days) | 1.2M | ★ 5.3M |
| Earning Date | 02-12-2026 | 02-04-2026 |
| Dividend Yield | N/A | ★ 2.08% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,467,400,000.00 |
| Revenue This Year | N/A | $15.16 |
| Revenue Next Year | N/A | $6.74 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.24 | $12.17 |
| 52 Week High | $47.65 | $44.78 |
| Indicator | MLYS | FMC |
|---|---|---|
| Relative Strength Index (RSI) | 44.90 | 54.92 |
| Support Level | $28.17 | $12.48 |
| Resistance Level | $31.83 | $16.97 |
| Average True Range (ATR) | 1.67 | 0.96 |
| MACD | 0.11 | -0.08 |
| Stochastic Oscillator | 48.77 | 79.87 |
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
FMC is a pure-play global crop protection company with a fairly balanced product portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop protection companies and focuses on the development of new products, including biologicals, through its research and development pipeline.